Anti-resorptive agents-related osteonecrosis of the jaw（ARONJ）患者の腐骨分離症例における悪性腫瘍患者と骨粗鬆症患者の比較

抄録

Objectives: There are an increasing number of reports that surgical treatment for antiresorptive agent-related osteonecrosis of the jaw （ARONJ） is more effective than conservative treatment, but there are not many reports on conservative treatment for ARONJ. Therefore, we report a clinical analysis of cases that underwent sequestration in conservative treatment for ARONJ.
Materials and Methods: In our department, 24 patients with ARONJ who underwent sequestration and 16 patients with ARONJ who did not undergo sequestration among 40 patients who underwent conservative treatment were analyzed retrospectively. If it was possible to stop administering antiresorptive agents, patients stopped receiving it. The 18 patients had received zoledronate or denosumab for metastatic bone tumors or multiple myeloma, and 22 had received bisphosphonates （BPs） for osteoporosis.
Results: All patients who underwent sequestration achieved complete cure by epithelization after sequestration. The follow-up period to sequestration in patients receiving zoledronate and denosumab for metastatic bone tumors or multiple myeloma was significantly longer than in patients receiving BPs for osteoporosis.
Conclusions: Conservative treatment of waiting for sequestration is a useful procedure for the treatment of ARONJ, if it is possible to stop administering the antiresorptive agents.